Policy & Regulation
Fusion Pharmaceuticals names new SVP, business development
22 September 2021 -

Fusion Pharmaceuticals Inc (Nasdaq: FUSN), a clinical-stage oncology company, announced on Tuesday that it has named Eric S Hoffman, PhD as its new senior vice president, business development.

Dr Hoffman has over 15 years' experience in the biotechnology industry. He has served as chief business officer at Vicarius Pharma, chief business officer of Genocea Biosciences, vice president of corporate and business development and executive director of investor relations and corporate communications at Idenix Pharmaceuticals.

Previously Dr Hoffman was director of corporate and business development and director of investor relations at Biogen Idec. He has also served for over five years on Wall Street as a biotechnology equity analyst at JPMorgan Securities and a biotechnology research associate at Bear Stearns International.

Dr Hoffman was a post-doctoral research associate in the Department of Immunobiology at King's College in London. He has a PhD in molecular, cellular and developmental biology with a focus on T cell immunology from Yale University, and a BS in biology from Trinity University.